Ignite Creation Date:
2025-12-25 @ 3:46 AM
Ignite Modification Date:
2025-12-26 @ 2:33 AM
Study NCT ID:
NCT05857202
Status:
UNKNOWN
Last Update Posted:
2023-05-12
First Post:
2023-03-29
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Oxidative Stress and Inflammation Biomarkers in Surgically Treated Patients With Laryngeal Cancer
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D007822', 'term': 'Laryngeal Neoplasms'}, {'id': 'D000377', 'term': 'Agnosia'}, {'id': 'D010149', 'term': 'Pain, Postoperative'}], 'ancestors': [{'id': 'D010039', 'term': 'Otorhinolaryngologic Neoplasms'}, {'id': 'D006258', 'term': 'Head and Neck Neoplasms'}, {'id': 'D009371', 'term': 'Neoplasms by Site'}, {'id': 'D009369', 'term': 'Neoplasms'}, {'id': 'D007818', 'term': 'Laryngeal Diseases'}, {'id': 'D012140', 'term': 'Respiratory Tract Diseases'}, {'id': 'D012142', 'term': 'Respiratory Tract Neoplasms'}, {'id': 'D010038', 'term': 'Otorhinolaryngologic Diseases'}, {'id': 'D010468', 'term': 'Perceptual Disorders'}, {'id': 'D019954', 'term': 'Neurobehavioral Manifestations'}, {'id': 'D009461', 'term': 'Neurologic Manifestations'}, {'id': 'D009422', 'term': 'Nervous System Diseases'}, {'id': 'D012816', 'term': 'Signs and Symptoms'}, {'id': 'D013568', 'term': 'Pathological Conditions, Signs and Symptoms'}, {'id': 'D011183', 'term': 'Postoperative Complications'}, {'id': 'D010335', 'term': 'Pathologic Processes'}, {'id': 'D010146', 'term': 'Pain'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D000701', 'term': 'Analgesics, Opioid'}, {'id': 'D018712', 'term': 'Analgesics, Non-Narcotic'}], 'ancestors': [{'id': 'D009294', 'term': 'Narcotics'}, {'id': 'D002492', 'term': 'Central Nervous System Depressants'}, {'id': 'D045505', 'term': 'Physiological Effects of Drugs'}, {'id': 'D020228', 'term': 'Pharmacologic Actions'}, {'id': 'D020164', 'term': 'Chemical Actions and Uses'}, {'id': 'D000700', 'term': 'Analgesics'}, {'id': 'D018689', 'term': 'Sensory System Agents'}, {'id': 'D018373', 'term': 'Peripheral Nervous System Agents'}, {'id': 'D002491', 'term': 'Central Nervous System Agents'}, {'id': 'D045506', 'term': 'Therapeutic Uses'}]}}, 'protocolSection': {'designModule': {'bioSpec': {'retention': 'SAMPLES_WITHOUT_DNA', 'description': 'Blood samples that were taken from the patients for the analysis of oxidative stress (glutathione peroxidase 1, superoxide dismutase 1 and malondialdehyde) parameters and inflammation parameters (interleukin 1 and 6) before the operative treatment and after the operative treatment (1 postoperative day and 7 postoperative day).'}, 'studyType': 'OBSERVATIONAL', 'designInfo': {'timePerspective': 'PROSPECTIVE', 'observationalModel': 'COHORT'}, 'enrollmentInfo': {'type': 'ESTIMATED', 'count': 100}, 'patientRegistry': False}, 'statusModule': {'overallStatus': 'UNKNOWN', 'lastKnownStatus': 'RECRUITING', 'startDateStruct': {'date': '2022-09-01', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2023-05', 'completionDateStruct': {'date': '2023-10-30', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2023-05-10', 'studyFirstSubmitDate': '2023-03-29', 'studyFirstSubmitQcDate': '2023-05-10', 'lastUpdatePostDateStruct': {'date': '2023-05-12', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2023-05-12', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2023-09-01', 'type': 'ESTIMATED'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Correlation between inflammatory marker IL-1 and pain intensity', 'timeFrame': '7 days', 'description': "A positive correlation between concentration of inflammatory marker IL-1 and pain intensity (VAS score) in postoperatively in surgically treated patients with laryngeal cancer is expected.\n\nThe concentrations of inflammatory parameters IL-1 (pg/mL) in the blood serum were determined by ELISA kits, according to the manufacturer's instructions.\n\nPain intensity would be assessed using the visual analog scale (VAS). Scores were based on self-reported measures of pain severity recorded with a mark placed at one point along the length of a 10-cm line that represents a continuum between the two ends of the scale (0 mm on the left end of the scale marks ''no pain'' and 100mm on the right end of the scale marks ''the worst pain'').\n\nCorrelation would be calculated with Spearman's rank correlation coefficient."}, {'measure': 'Correlation between inflammatory marker IL-6 and pain intensity', 'timeFrame': '7 days', 'description': "A positive correlation between concentration of inflammatory marker IL-6 and pain intensity (VAS score) in postoperatively in surgically treated patients with laryngeal cancer is expected.\n\nThe concentrations of inflammatory marker IL-6 (pg/mL) in the blood serum were determined by ELISA kits, according to the manufacturer's instructions.\n\nPain intensity would be assessed using the visual analog scale (VAS). Scores were based on self-reported measures of pain severity recorded with a mark placed at one point along the length of a 10-cm line that represents a continuum between the two ends of the scale (0 mm on the left end of the scale marks ''no pain'' and 100mm on the right end of the scale marks ''the worst pain'').\n\nCorrelation would be calculated with Spearman's rank correlation coefficient."}, {'measure': 'Correlation between inflammatory marker CRP and pain intensity', 'timeFrame': '7 days', 'description': "A positive correlation between concentration of inflammatory marker CRP and pain intensity (VAS score) in postoperatively in surgically treated patients with laryngeal cancer is expected.\n\nThe concentrations of inflammatory marker CRP (ng/mL) in the blood serum were determined by ELISA kits, according to the manufacturer's instructions.\n\nPain intensity would be assessed using the visual analog scale (VAS). Scores were based on self-reported measures of pain severity recorded with a mark placed at one point along the length of a 10-cm line that represents a continuum between the two ends of the scale (0 mm on the left end of the scale marks ''no pain'' and 100mm on the right end of the scale marks ''the worst pain'').\n\nCorrelation would be calculated with Spearman's rank correlation coefficient."}, {'measure': 'Correlation between oxidative stress marker MDA and pain intensity', 'timeFrame': '7 days', 'description': "A positive correlation between concentration of oxidative stress marker MDA and pain intensity (VAS score) in postoperatively in surgically treated patients with laryngeal cancer is expected.\n\nThe concentrations of oxidative stress marker MDA (ng/mL) in the blood serum were determined by ELISA kits, according to the manufacturer's instructions.\n\nPain intensity would be assessed using the visual analog scale (VAS). Scores were based on self-reported measures of pain severity recorded with a mark placed at one point along the length of a 10-cm line that represents a continuum between the two ends of the scale (0 mm on the left end of the scale marks ''no pain'' and 100mm on the right end of the scale marks ''the worst pain'').\n\nCorrelation would be calculated with Spearman's rank correlation coefficient."}, {'measure': 'Correlation between anti- oxidative stress marker SOD and pain intensity', 'timeFrame': '7 days', 'description': "A negative correlation between concentration of anti-oxidative stress marker SOD and pain intensity (VAS score) in postoperatively in surgically treated patients with laryngeal cancer is expected.\n\nThe concentrations of anti-oxidative stress marker SOD (pg/mL) in the blood serum were determined by ELISA kits, according to the manufacturer's instructions.\n\nPain intensity would be assessed using the visual analog scale (VAS). Scores were based on self-reported measures of pain severity recorded with a mark placed at one point along the length of a 10-cm line that represents a continuum between the two ends of the scale (0 mm on the left end of the scale marks ''no pain'' and 100mm on the right end of the scale marks ''the worst pain'').\n\nCorrelation would be calculated with Spearman's rank correlation coefficient."}, {'measure': 'Correlation between anti- oxidative stress marker GPX1 and pain intensity', 'timeFrame': '7 days', 'description': "A negative correlation between concentration of anti- oxidative stress marker GPX1 and pain intensity (VAS score) in postoperatively in surgically treated patients with laryngeal cancer is expected.\n\nThe concentrations of anti-oxidative stress marker GPX1 (pg/mL) in the blood serum were determined by ELISA kits, according to the manufacturer's instructions.\n\nPain intensity would be assessed using the visual analog scale (VAS). Scores were based on self-reported measures of pain severity recorded with a mark placed at one point along the length of a 10-cm line that represents a continuum between the two ends of the scale (0 mm on the left end of the scale marks ''no pain'' and 100mm on the right end of the scale marks ''the worst pain'').\n\nCorrelation would be calculated with Spearman's rank correlation coefficient."}]}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'keywords': ['oxidative stress', 'laryngeal cancer', 'pain management', 'interleukins'], 'conditions': ['Oxidative Stress Induction', 'Laryngeal Cancer', 'Interleukins', 'Pain Management', 'Quality of Life', 'Pain, Postoperative']}, 'referencesModule': {'references': [{'pmid': '29720267', 'type': 'BACKGROUND', 'citation': 'Hinther A, Nakoneshny SC, Chandarana SP, Wayne Matthews T, Dort JC. Efficacy of postoperative pain management in head and neck cancer patients. J Otolaryngol Head Neck Surg. 2018 May 2;47(1):29. doi: 10.1186/s40463-018-0274-y.'}, {'pmid': '28441057', 'type': 'BACKGROUND', 'citation': 'Sies H, Berndt C, Jones DP. Oxidative Stress. Annu Rev Biochem. 2017 Jun 20;86:715-748. doi: 10.1146/annurev-biochem-061516-045037. Epub 2017 Apr 24.'}, {'pmid': '35048046', 'type': 'BACKGROUND', 'citation': 'Niklander SE, Murdoch C, Hunter KD. IL-1/IL-1R Signaling in Head and Neck Cancer. Front Oral Health. 2021 Aug 26;2:722676. doi: 10.3389/froh.2021.722676. eCollection 2021.'}, {'pmid': '28179349', 'type': 'RESULT', 'citation': 'Purdy M, Karkkainen J, Kokki M, Anttila M, Aspinen S, Juvonen P, Kokki H, Pulkki K, Rantanen T, Eskelinen M. Does Rectus Sheath Block Analgesia Alter Levels of the Oxidative Stress Biomarker Glutathione Peroxidase: A Randomised Trial of Patients with Cancer and Benign Disease. Anticancer Res. 2017 Feb;37(2):897-902. doi: 10.21873/anticanres.11396.'}, {'pmid': '17822322', 'type': 'RESULT', 'citation': 'Salzman R, Kankova K, Pacal L, Tomandl J, Horakova Z, Kostrica R. Increased activity of superoxide dismutase in advanced stages of head and neck squamous cell carcinoma with locoregional metastases. Neoplasma. 2007;54(4):321-5.'}, {'pmid': '33587847', 'type': 'RESULT', 'citation': 'Uz U, Eskiizmir G. Association Between Interleukin-6 and Head and Neck Squamous Cell Carcinoma: A Systematic Review. Clin Exp Otorhinolaryngol. 2021 Feb;14(1):50-60. doi: 10.21053/ceo.2019.00906. Epub 2021 Feb 1.'}, {'pmid': '26135695', 'type': 'RESULT', 'citation': 'Rettig TC, Verwijmeren L, Dijkstra IM, Boerma D, van de Garde EM, Noordzij PG. Postoperative Interleukin-6 Level and Early Detection of Complications After Elective Major Abdominal Surgery. Ann Surg. 2016 Jun;263(6):1207-12. doi: 10.1097/SLA.0000000000001342.'}, {'pmid': '29374733', 'type': 'RESULT', 'citation': 'Karkkainen J, Selander T, Purdy M, Juvonen P, Eskelinen M. Patients with Increased Levels of the Oxidative Stress Biomarker SOD1 Appear to Have Diminished Postoperative Pain After Midline Laparotomy: A Randomised Trial with Special Reference to Postoperative Pain Score (NRS). Anticancer Res. 2018 Feb;38(2):1003-1008. doi: 10.21873/anticanres.12315.'}, {'pmid': '32538771', 'type': 'RESULT', 'citation': 'Liu Q, Xu K. Evaluation of some cellular biomarker proteins, oxidative stress and clinical indices as results of laparoscopic appendectomy for perforated appendicitis in children. Cell Mol Biol (Noisy-le-grand). 2020 Jun 5;66(3):197-203.'}, {'pmid': '28623906', 'type': 'RESULT', 'citation': 'Si HB, Yang TM, Zeng Y, Zhou ZK, Pei FX, Lu YR, Cheng JQ, Shen B. Correlations between inflammatory cytokines, muscle damage markers and acute postoperative pain following primary total knee arthroplasty. BMC Musculoskelet Disord. 2017 Jun 17;18(1):265. doi: 10.1186/s12891-017-1597-y.'}, {'pmid': '31785250', 'type': 'RESULT', 'citation': 'Xi MY, Li SS, Zhang C, Zhang L, Wang T, Yu C. Nalbuphine for Analgesia After Orthognathic Surgery and Its Effect on Postoperative Inflammatory and Oxidative Stress: A Randomized Double-Blind Controlled Trial. J Oral Maxillofac Surg. 2020 Apr;78(4):528-537. doi: 10.1016/j.joms.2019.10.017. Epub 2019 Nov 5.'}, {'pmid': '35869710', 'type': 'RESULT', 'citation': 'Liu D, Liu H, Wu J, Gong B. Effects of Thoracic Paravertebral Blockon Inflammatory Response, Stress Response, Hemodynamics and Anesthesia Resuscitation inGallbladder Carcinoma. Cell Mol Biol (Noisy-le-grand). 2022 Feb 28;68(2):171-177. doi: 10.14715/cmb/2022.68.2.24.'}, {'pmid': '39682700', 'type': 'DERIVED', 'citation': 'Zivkovic A, Jotic A, Dozic I, Randjelovic S, Cirkovic I, Medic B, Milovanovic J, Trivic A, Korugic A, Vukasinovic I, Savic Vujovic K. Role of Oxidative Stress and Inflammation in Postoperative Complications and Quality of Life After Laryngeal Cancer Surgery. Cells. 2024 Nov 23;13(23):1951. doi: 10.3390/cells13231951.'}]}, 'descriptionModule': {'briefSummary': 'A experimental interventional prospective study will include patients with squamocellular carcinoma of the larynx surgically treated at the tertiary referral center. Clinical and demographic characteristics of the patients would be noted. The visual analog scale (VAS), Brief Pain Inventory questionnaire, Diagnosing Neuropathic Pain 4 (DN4) and Pain Detect Questionnaire were used for pain assessment. Questionnaire Quality of Life in Head and Neck Cancer Patients (QLQ - H\\&N35) was used to assess the quality of life in patients with surgically treated laryngeal carcinoma. The type and consumption of analgesics used after surgery was monitored. The analgesics were used according to WHO Ladder. Blood samples ware taken from the patients for the analysis of oxidative stress parameters and inflammation parameters before the operative treatment and after the operative treatment (1-2 postoperative day and 9-10 postoperative day). The concentrations of interleukin 1 (IL-1) and 6 (IL-6), glutathione peroxidase 1 (GPX1), superoxide dismutase 1 (SOD1) and malondialdehyde (MDA) in the serum were determined.\n\nThe aim of the study will be to assess concentrations of inflammatory biomarkers (IL-1, IL-6) and oxidative stress factors (MDA, SOD, GPKS1) in postoperative course in surgically treated patients with laryngeal carcinoma and in possible complication occurrence. Also, their correlation to type and dosage of used analgesics, to pain assessment questionnaire scores and QOL questionnaire scores in surgically treated patients with laryngeal carcinoma will be assessed.', 'detailedDescription': "Patient selection\n\nA experimental interventional prospective study would include 100 patients with squamocellular carcinoma of the larynx surgically treated in the period from October 2022 to February 2023 at the tertiary referral center. This study was approved by the Institutional Ethics Committee (745/5-22), and all patients signed the informed consent form prior to their inclusion in the study. The diagnosis of laryngeal carcinoma was confirmed by otorhinolaryngological clinical examination and laryngomicroscopic examination of the larynx with the biopsy and histopathologic examination of the tissue. Additional diagnostics (chest radiography and computed tomography of the neck and ultrasonography of the abdomen) were performed to determine the TNM stage of the disease. Study included patients with all stages of operable laryngeal carcinoma (T1-T4, N0-N2), without previous treated malignancies. Exclusion criteria were inoperable malignant disease, presence of distant metastases, previously treated malignancies, presence of neurological or other severe comorbidities which prevent surgical treatment, the presence of neurological or other severe physical and metabolic comorbidities, substance abuse, and the inability to provide informed consent.\n\nThe modality of treatment for every patient was decided on the institutional Oncological Board (consisting of a radiotherapist, head and neck surgeons, an oncologist, and a histopathologist). Open surgical treatment involved resection of the tumor (cordectomy, partial or total laryngectomy) with or without some form of the neck dissection in case of cervical lymphadenopathy. Demographic, clinical and histopathological characteristics (age and gender, tobacco use, histopathological tumor grade, TNM classification, and therapy modality) were noted.\n\nQuality of life assessment\n\nQuestionnaire Quality of Life in Head and Neck Cancer Patients (QLQ - H\\&N35) was used to assess the quality of life in patients with surgically treated laryngeal carcinoma.\n\nPain assessment\n\nThe visual analog scale (VAS) was used for pain assessment. Scores were based on self-reported measures of pain severety that are recorded with a mark placed at one point along the length of a 10-cm line that represents a continuum between the two ends of the scale (0 cm on the left end of the scale marks ''no pain'' and 10 cm on the right end of the scale marks ''the worst pain'').\n\nBrief Pain Inventory questionnaire, Diagnosing Neuropathic Pain 4 (DN4) and Pain Detect Questionnaire were used for quality assessment of postoperative pain\n\nPostoperative analgesia\n\nThe type and consumption of analgesics used after surgery was monitored. The analgesics were used according to WHO Ladder: (1) for mild to moderate pain, a non-opioid (acetaminophen or non-steroid anti-inflammatory drug , NSAID) with or without an adjuvant; (2) for moderate or severe pain, a non-opioid with an opioid for moderate pain and (3) an opioid for moderate to severe pain not combined with another agent.\n\nMeasurement of the Oxidative Stress and Inflammatory Parameters\n\nBlood was taken from the patients for the analysis of oxidative stress parameters and inflammation parameters before the operative treatment and after the operative treatment (1-2 postoperative day and 9-10 postoperative day). The concentrations of interleukin 1 (IL-1) and 6 (IL-6), glutathione peroxidase 1 (GPX1), superoxide dismutase 1 (SOD1) and malondialdehyde (MDA) in the serum were determined by coated enzyme-linked immunosorbent assay (ELISA) kits, according to the manufacturer's instructions (Elabscience, Wuhan, China). The ELISA kits for determination of concentrations of IL-1 and IL-6 were based on the Sandwich ELISA principle, with plates pre-coated with an antibody specific to human cytokines. The optical density (OD) was measured spectrophotometrically at 450 nm, using a Multiskan EX plate reader (Thermo Fisher Scientific, Vantaa, Finland). The concentration of analytesin of the tested samples was calculated by comparing the OD of the samples to the standard curve created with GraphPad Prism 9.0 software (GraphPad Software Inc., San Diego, CA, USA).\n\nStatistical analysis\n\nCategorical data was described by absolute and relative numbers (in percentages), while numerical data was reported as arithmetic mean and standard deviation or median and interquartile range (IQR), depending on the data distribution. The normality was evaluated using mathematical (Shapiro-Willk, skewness and kurtosis, and coefficient of variation) and graphical (histogram, box plot) methods. For the evaluation of changing of pain intensity, parameters of oxidative stress, and biomarkers of inflammation Friedman test was applied with Wilcoxon signed rank test as post-hoc testing method. For analyzing the association between pain intensity (VAS), parameters of oxidative stress, and biomarkers of inflammation Spearman's rank correlation coefficient was used, because variables didn't have normal distribution. In order to evaluate all possible factors that influence the level of oxidative stress expressed as SOD and MDA levels, linear regression analysis (enter method) was performed reporting regression coefficient B, 95% confidence level (CI) of B, and p value. Univariate analysis was done first, and all significant factors were combined in multivariate models. All statistical methods were considered significant if p value was less or equal 0.05. The analysis was performed in IBM SPSS ver. 26."}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'maximumAge': '85 Years', 'minimumAge': '18 Years', 'samplingMethod': 'NON_PROBABILITY_SAMPLE', 'studyPopulation': 'The study would include 100 patients with squamocellular carcinoma of the larynx surgically treated at the tertiary referral center. The diagnosis of laryngeal carcinoma was confirmed by otorhinolaryngological clinical examination, laryngomicroscopic examination with the biopsy and histopathologic examination. Additional diagnostics (chest radiography and computed tomography of the neck and ultrasonography of the abdomen) were performed to determine the TNM stage of the disease.\n\nThe modality of surgical treatment was decided on the institutional Oncological Board and involved resection of the tumor (cordectomy, partial or total laryngectomy) with or without some form of the neck dissection in case of cervical lymphadenopathy.', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* patients with all stages of diagnosed and operable laryngeal squamocellular carcinoma (T1-T4, N0-N2)\n\nExclusion Criteria:\n\n* inoperable malignant disease\n* presence of distant metastases\n* previously treated malignancies\n* presence of neurological or other severe comorbidities which prevent surgical treatment\n* the presence of neurological or other severe physical and metabolic comorbidities\n* substance abuse\n* the inability to provide informed consent.'}, 'identificationModule': {'nctId': 'NCT05857202', 'briefTitle': 'Oxidative Stress and Inflammation Biomarkers in Surgically Treated Patients With Laryngeal Cancer', 'organization': {'class': 'OTHER', 'fullName': 'Clinical Centre of Serbia'}, 'officialTitle': 'Oxidative Stress and Inflammation Biomarkers in Correlation to Postoperative Pain Modulation in Surgically Treated Patients With Laryngeal Cancer', 'orgStudyIdInfo': {'id': '754/5'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Operated laryngeal cancer patients treated with non narcotic', 'description': 'Operated laryngeal cancer patients who were administered non narcotic drugs postoperative for pain management', 'interventionNames': ['Drug: Analgesics, Non-Narcotic']}, {'label': 'Operated laryngeal cancer patients treated with non narcotic and opioids', 'description': 'Operated laryngeal cancer patients who were administered non narcotic and opioids postoperative for pain management', 'interventionNames': ['Drug: Analgesics, Opioid', 'Drug: Analgesics, Non-Narcotic']}, {'label': 'Operated laryngeal cancer patients treated with opioids', 'description': 'Operated laryngeal cancer patients who were administered opioids postoperative for pain management', 'interventionNames': ['Drug: Analgesics, Opioid']}], 'interventions': [{'name': 'Analgesics, Opioid', 'type': 'DRUG', 'description': 'Drugs were given immediately after the surgery, and correlation between analgesic use and parameters of oxidative stress and inflammation was assessed.', 'armGroupLabels': ['Operated laryngeal cancer patients treated with non narcotic and opioids', 'Operated laryngeal cancer patients treated with opioids']}, {'name': 'Analgesics, Non-Narcotic', 'type': 'DRUG', 'description': 'Drugs were given immediately after the surgery, and correlation between analgesic use and parameters of oxidative stress and inflammation was assessed.', 'armGroupLabels': ['Operated laryngeal cancer patients treated with non narcotic', 'Operated laryngeal cancer patients treated with non narcotic and opioids']}]}, 'contactsLocationsModule': {'locations': [{'zip': '11000', 'city': 'Belgrade', 'status': 'RECRUITING', 'country': 'Serbia', 'contacts': [{'name': 'Ana D Jotic, MD, PhD', 'role': 'CONTACT', 'email': 'anajotic@yahoo.com', 'phone': '+381637789825'}], 'facility': 'Clinic for otorhinolaryngology and maxillofacial surgery, Clinical Center of Serbia', 'geoPoint': {'lat': 44.80401, 'lon': 20.46513}}, {'zip': '11000', 'city': 'Belgrade', 'status': 'RECRUITING', 'country': 'Serbia', 'contacts': [{'name': 'Katarina R Savic Vujovic, MD, PhD', 'role': 'CONTACT', 'email': 'katarinasavicvujovic@gmail.com', 'phone': '+381 63 776 3960'}, {'name': 'Andjela T Zivkovic, MD', 'role': 'SUB_INVESTIGATOR'}], 'facility': 'Clinical Pharmacology and Toxicology, Faculty of Medicine, University of Belgrade', 'geoPoint': {'lat': 44.80401, 'lon': 20.46513}}], 'centralContacts': [{'name': 'Ana D Jotic, MD, PHD', 'role': 'CONTACT', 'email': 'anajotic@yahoo.com', 'phone': '+381 63 7789825'}, {'name': 'Jovica M Milovanovic, MD, PhD', 'role': 'CONTACT', 'email': 'jmtmilov@gmail.com', 'phone': '+381 63 7707374'}], 'overallOfficials': [{'name': 'Ana D Jotic, MD, PhD', 'role': 'STUDY_DIRECTOR', 'affiliation': 'Clinic for otorhinolaryngology and maxillofacial surgery, Clinical center of Serbia'}, {'name': 'Katarina R Savic Vujovic, MD, PhD', 'role': 'STUDY_DIRECTOR', 'affiliation': 'Clinical Pharmacology and Toxicology, Faculty of Medicine, University of Belgrade'}]}, 'ipdSharingStatementModule': {'infoTypes': ['STUDY_PROTOCOL', 'SAP', 'ICF'], 'timeFrame': '12 months after completion of the study', 'ipdSharing': 'YES', 'description': 'Available and ethical compliant patients data will be submitted to the data repository', 'accessCriteria': 'Interested investigators can access the data through available link'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Clinical Centre of Serbia', 'class': 'OTHER'}, 'collaborators': [{'name': 'Faculty of Medicine, University of Belgrade', 'class': 'UNKNOWN'}], 'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR', 'investigatorTitle': 'Assistant professor, MD, PhD', 'investigatorFullName': 'Ana Jotić', 'investigatorAffiliation': 'Clinical Centre of Serbia'}}}}